Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-oleyl-phosphatidyl-ethanolamine (NOPE) is a naturally occurring phospholipid found in cell membranes and various food sources, currently utilized as a dietary supplement for weight management and the treatment of obesity. Upon oral ingestion, NOPE is hydrolyzed by phospholipase D in the gastrointestinal tract to produce N-oleyl-ethanolamide (NOE) and phosphatidic acid. NOE serves as the primary bioactive component, functioning as a satiety factor that regulates food intake. Its mechanism involves the activation of Peroxisome proliferator-activated receptor alpha (PPAR-alpha) and the indirect modulation of the endocannabinoid system by inhibiting the effects of anandamide on Cannabinoid receptor 1 (CB1). NOPE is frequently commercialized in combination with epigallocatechin-3-gallate (EGCG) from green tea extract, a pairing designed to enhance metabolic rate and improve compliance with calorie-restricted diets. Clinical studies have demonstrated its potential to reduce appetite and improve body composition in overweight and obese populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-oleyl-phosphatidyl-ethanolamine.